efficacy and safety of telbivudine compared to entecavir among hbeag+ chronic hepatitis b patients: a meta-analysis study

background hepatitis b virus (hbv) infection is a serious global health problem that is associated with huge social and economic costs. early antiviral drugs, such as interferon-α2b, peginterferon-α2a, lamivudine, and adefovir, all have their limitations (such as low responses or safety concerns) in clinical application. telbivudine and entecavir are two of the latest nucleotide drugs and both have been shown to have potent viral suppression. however, in patients with hepatitis b e antigen (hbeag)-positive chronic hepatitis b (chb), inconsistent results have been generated for efficacy between telbivudine and entecavir. therefore, evidence-based medical data are required to compare the efficacies, in terms of virological and biochemical responses, and safety between telbivudine and entecavir. objectives we aimed to compare the early antiviral efficacy and safety of telbivudine and entecavir in the treatment of patients with hepatitis b e antigen (hbeag)-positive chronic hepatitis b (chb). patients and methods a search for relevant randomized controlled trials (rcts) on hbeag-positive chb patients treated with telbivudine and entecavir for 24 or 52 weeks, published before december 2011, was performed. primary efficacy endpoint was the cumulative rate of undetectable hbv dna, and secondary efficacy endpoints included rates of alanine aminotransferase (alt) normalization, hbeag disappearance, hbeag seroconversion and adverse events. meta-analysis was performed using the review manager v5.1.4 software package. we assessed the pooled risk ratios (rrs) and 95% confidence intervals (cis) using the fixed-or random-effects model. results six randomized controlled trials (rcts) involving 555 patients were included. telbivudine was associated with significantly higher rates of hbeag disappearance (rr = 1.46, 95% ci: 1.11 - 1.91) and hbeag seroconversion (rr = 1.76, 95%ci: 1.25-2.48) than entecavir, but had higher adverse events (rr = 2.11, 95%ci: 1.23 - 3.60), compared with entecavir. there was no difference between telbivudine and entecavir in the rate of cumulative undetectable hbv dna (rr = 0.99, 95% ci: 0.90 - 1.10) and alt normalization (rr = 0.93, 95% ci: 0.85 - 1.00). conclusions telbivudine is associated with significantly higher rates of hbeag disappearance and hbeag seroconversion than entecavir, whereas entecavir is superior to telbivudine in safety. both drugs have similar efficacy on rates of cumulative undetectable hbv dna and alt normalization.